The drug effectiveness review project: An important step forward

Health Affairs

Volumn 25, Issue 4, 2006, Pages

  Gibson, Mark ^a   Santa, John ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Drug Effectiveness Review Project (DERP)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DECISION MAKING; DRUG USE; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PUBLICATION; REVIEW;

COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG UTILIZATION REVIEW; EFFICIENCY, ORGANIZATIONAL; EVIDENCE-BASED MEDICINE; FORMULARIES; HEALTH CARE COALITIONS; HUMANS;

EID: 33746874069     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.w272     Document Type: Review

References (11)

1. P.J. Neumann, "Emerging Lessons from the Drug Effectiveness Review Project," Health Affairs 25 (2006): w262-w271 (published online 6 June 2006; 10.1377/hlthaff.25.w262).
2. P. Juni, A.W. Rutjes, and P.A. Dieppe, "Are Selective COX 2 Inhibitors Superior to Traditional Non Steroidal Anti-inflammatory Drugs?" British Medical Journal 324, no. 7349 (2002): 1287-1288.
3. D.L. Sackett et al., "Evidence Based Medicine: What It Is and What It Isn't," British Medical Journal 312, no. 7023 (1996): 71-72.
4. Oregon Health and Science University, "Drug Effectiveness Review Project: Description," http://www.ohsu.edu/drugeffectiveness/description/ index.htm (accessed 12 May 2006).
5. S. Carson, M.S. McDonagh, and K. Peterson, "A Systematic Review of the Efficacy and Safety of Atypical Antipsychotics in Patients with Psychological and Behavioral Symptoms of Dementia," Journal of the American Geriatrics Society 54, no. 2 (2006): 354-361;
6. R. Chou, K. Peterson, and M. Helfand, "Comparative Efficacy and Safety of Skeletal Muscle Relaxants for Spasticity and Musculoskeletal Conditions: A Systematic Review," Journal of Pain and Symptom Management 28, no. 2 (2004): 140-175;
7. G. Gartlehner et al., "Discontinuation Rates for Selective Serotonin Reuptake Inhibitors and Other Second-Generation Antidepressants in Outpatients with Major Depressive Disorder: A Systematic Review and Meta-analysis," International Clinical Psychopharmacology 20, no. 2 (2005): 59-69;
8. and R.A. Hansen et al., "Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder," Annals of Internal Medicine 143, no. 6 (2005): 415-426.
9. T.A. Brennan et al., "Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers," Journal of the American Medical Association 295, no. 4 (2006): 429-433.
10. See In the Circuit Court of the State of Oregon (for the County of Marion), IN THE MATTER OF WARNER LAMBERT COMPANY, LLC, Case no. 04C14403, 13 May 2004; and F. Goodman et al., Drug Class Review on Antiepileptic Drugs in Bipolar Mood Disorder and Neuropathic Pain, Final Report, December 2004, http://www.ohsu.edu/drugeffectiveness/reports/documents/ Antiepileptic%20Drugs%20Final%20Report.pdf (accessed 16 March 2006).
11. C.M. Bell et al., "Bias in Published Cost Effectiveness Studies: Systematic Review," British Medical Journal 332, no. 7543 (2006): 699-703.